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Abstract
Background: The European Organisation for Research and Treatment of Cancer (EORTC) Patient-Reported 
Outcomes and Behavioural Evidence (PROBE) initiative was established to investigate critical topics to better 
understand health-related quality of life (HRQOL) of cancer patients and to educate clinicians, policy makers, and 
healthcare providers.
Methods: The aim of this paper is to review the major research outcomes of the pooled analysis of HRQOL data along with 
the clinical data. We identified 30 pooled EORTC randomized controlled trials (RCTs), 18 NCIC-Clinical Trials Group RCTs, 
and two German Ovarian Cancer Study Group RCTs, all using the EORTC QLQ-C30. All statistical tests were two-sided.
Results: Evidence was found that HRQOL data can offer prognostic information beyond clinical measures and improve 
prognostic accuracy in cancer RCTs (by 5.9%-8.3%). Moreover, models that considered both patient- and clinician-reported 
scores gained more prognostic overall survival accuracy for fatigue (P < .001), vomiting (P = .01), nausea (P < .001), and 
constipation (P = .01). Greater understanding of the association between symptom and/or functioning scales was developed 
by identifying physical, psychological, and gastrointestinal clusters. Additionally, minimally important differences in 
interpreting HRQOL changes for improvement and deterioration were found to vary across different patient populations 
and disease stages. Finally, HRQOL scores are statistically significantly affected by deviations from the intended time point 
at which the questionnaire is completed.
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Conclusions: The use of existing pooled data shows that it is possible to learn about general aspects of cancer HRQOL 
and methodology. Our work shows that setting up international pooled datasets holds great promise for understanding 
patients’ unmet psychosocial needs and calls for additional empirical investigation to improve clinical care and understand 
cancer through retrospective HRQOL analyses.
The demand for symptom relief, reduced side effects of medi-
cal strategies, and improved patient satisfaction with care led 
to the increased collection and analysis of patient-reported 
health-related quality of life (HRQOL) data. Such data help 
determine the effectiveness of clinical interventions from the 
patient perspective. Yet several methodological issues remain 
in the assessment, analysis, and interpretation of HRQOL data 
from clinical trials. We pooled the data of multiple closed rand-
omized controlled trials (RCTs) in order to address a number of 
methodological questions of relevance to the field that were not 
addressed by the original trials. An overview of the results of the 
European Organisation for Research and Treatment of Cancer 
(EORTC) Patient-Reported Outcomes and Behavioural Evidence 
(PROBE) project (1) initiative are reported here.
The PROBE project was launched in January 2008 as an ini-
tiative of the EORTC Quality of Life Department (QLD). QLD has 
provided support and expertise toward the inclusion of HRQOL 
endpoints in EORTC RCTs since 1993, following the development 
and publication of the EORTC Quality of Life Core Questionnaire 
(QLQ-C30) (2). The QLQ-C30 is comprised of 30 questions meas-
uring fifteen HRQOL parameters: five functioning scales (physi-
cal, role, cognitive, emotional, and social), three symptom scales 
(pain, fatigue, nausea/vomiting), six single items (dyspnea, 
insomnia, appetite loss, constipation, diarrhea, and financial 
problems), and global health status/quality of life. All scales and 
single item measures range in score from 0 to 100. Higher scores 
represent better health for the functional scales and the global 
health status/quality of life scale while for the symptom scales 
and the symptom items higher scores represent worse health. 
The QLQ-C30, which is applicable to the general cancer popula-
tion, has become the most widely used HRQOL questionnaire in 
cancer RCTs during the last two decades (3–7).
This review arises from the activities of the EORTC PROBE 
initiative, which aimed to develop a user-ready HRQOL database 
of scores collected on the QLQ-C30 and to use it to investigate 
general research questions common across different cancer 
types. Collecting data from closed international oncology RCTs 
that informed clinical practice over the years (8) has been 
challenging.
HRQOL data are collected and analyzed trial by trial and pub-
lished either together with clinical data or separately to measure 
the impact of cancer and its treatment on patients’ HRQOL. This 
leads inevitably to a fragmented body of evidence, often with 
inconsistent methods of data collection, analysis, and reporting. 
Construction of a meta-dataset, which pools data from differ-
ent cancer clinical trials across different patient populations 
(eg, lung, breast, melanoma) or disease stages (eg, primary vs 
advanced) can give a more comprehensive view of HRQOL in 
oncology. Moreover, it allows the application of analytical tech-
niques demanding large sample sizes in a field where data col-
lection is often very restricted and expensive. PROBE undertook 
the challenge to merge international RCTs and make meaning-
ful analyses of these data with the support of the PROBE interna-
tional advisory board (composed of medical, clinical, statistical, 
psychological, and other experts across different fields), which 
scrutinized the analyses and their interpretation and advised on 
the overall management of the research initiative.
PROBE had a specific mandate to focus on the practical appli-
cation of HRQOL in clinical trials research. The research objec-
tives identified by the PROBE team and reviewed in this article 
were therefore to assess the prognostic value of HRQOL for sur-
vival, to compare clinicians’ and patients’ HRQOL assessment 
for their prognostic value for overall survival (OS), to explore 
whether QLQ-C30 domains cluster, to investigate minimal 
important differences (MIDs) for interpreting HRQOL scores 
from the QLQ-C30, and to examine the effect of completion time 
windows on HRQOL outcomes (Figure 1).
Methods
The PROBE Dataset
Over the last 25  years, EORTC used HRQOL as a primary or 
secondary endpoint in over 150 clinical trials. Many of these 
Figure 1. The Patient-Reported Outcomes and Behavioural Evidence research agenda. HRQOL = health-related quality of life; MIDs = minimally important differences; 
PROBE = Patient-Reported Outcomes and Behavioural Evidence; QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Core Question-
naire; RCTs = randomized controlled trials.
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trials were either open to patient recruitment or the primary 
endpoint results were not yet published during the selection 
of trials (either because of early termination or primary end-
point being analyzed) or did not have good HRQOL compliance 
data, making it unfeasible to use those RCT data. Finally, thirty 
of these RCTs with QLQ-C30 data, good patient compliance, 
and where EORTC QLD obtained the permission for data use 
were selected. Those RCTs were conducted from 1986 to 2004, 
and included 10 874 patients from 11 different cancer sites. 
The data from these RCTs were extracted from the EORTC 
database and merged to form the PROBE database. In addi-
tion, other research organizations were invited to share their 
RCT data that used the QLQ-C30 and cancer-related modules. 
Permission for eighteen RCTs from the NCIC-Clinical Trials 
Group (NCIC-CTG), including 4635 patients’ data from 15 dif-
ferent cancer sites, and two ovarian cancer RCTs with 1731 
patients’ data from the German Ovarian Cancer Study Group 
(AGO) were obtained and shared via external software plat-
forms (Figure 2).
All selected international RCTs included HRQOL as a sec-
ondary outcome collected via the QLQ-C30. Standardized 
socio-demographic and clinical data (eg, age, sex, World Health 
Organization [WHO] performance status, and stage of disease) 
were also included. The PROBE database includes data from a 
total of 17 239 individual patients with completed QLQ-C30, with 
or without its supplementary modules, and clinical and survival 
outcomes.
Statistical Analysis
The different analysis techniques and statistical methods used 
in the reviewed research projects are fully reported within the 
references of the previously conducted analyses (9–17). All sta-
tistical tests were two-sided, and a P value of less than .05 was 
considered statistically significant.
Results
HRQOL Adds Prognostic Value Beyond Clinical 
Information
One of the key questions cancer patients ask their clinicians 
when diagnosed with cancer is ‘How long will I live?’ Research 
into prognostic indicators of survival is an important topic in 
oncology, and data from many single RCTs have identified 
various factors. A  previously published review of HRQOL data 
collected in cancer RCTs (5) indicated that HRQOL data are prog-
nostic of survival above and beyond clinical predictors. Among 
the 39 reviewed RCTs by Gotay et al. (5), four functioning (physi-
cal, role, social, emotional) and three symptom scales (pain, 
fatigue, nausea, and vomiting), along with four single items 
(appetite loss, dyspnea, insomnia, constipation) and global 
health status/quality of life, were reported to be prognostic of 
survival. Four PROBE analyses provided further evidence that 
HRQOL can improve the prognostic value in cancer clinical tri-
als (9–12).
First, Quinten et al. (9) examined the prognostic significance 
of socio-demographic (age and sex), clinical variables (WHO per-
formance status, distant metastasis, and cancer site) and the 15 
QLQ-C30 scales and individual items across different disease 
sites. In the Cox multivariable model including the aforemen-
tioned variables, the HRQOL domains physical functioning (P < 
.0001), pain (P < .0001) and appetite loss (P < .0001) provided sta-
tistically significant prognostic information in addition to age 
(P  =  .0001), sex (P < .0001), and distant metastases (P < .0001); 
meanwhile, the WHO performance status did not add prognos-
tic information (P  =  .11). The three HRQOL domains improved 
the estimation of survival by 5.9% relative to socio-demographic 
and clinical characteristics alone. A  second survival analysis 
(10) in a subgroup of 2410 metastatic cancer patients revealed 
that physical functioning, pain, and appetite loss, along with the 
Figure 2. The Patient-Reported Outcomes and Behavioural Evidence dataset subgrouped by cancer sites. AGO = German Ovarian Cancer Study Group; EORTC = Euro-
pean Organisation for Research and Treatment of Cancer; NCIC-CTG = NCIC-Clinical Trials Group; NSCLC = non–small cell lung cancer; PROBE = Patient-Reported 
Outcomes and Behavioural Evidence; SCLC = small cell lung cancer. 
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variables age, sex, and WHO performance status, increased prog-
nostic accuracy by 8.3% compared with clinical variables alone, 
thereby demonstrating that the prognostic value of HRQOL may 
differ across clinical subgroups.
The question then arose of whether or not different HRQOL 
domains are prognostic for survival for different cancer sites. 
By using a dataset of 7417 patients who completed the QLQ-
C30 before randomization, Quinten et al. (11) found that at least 
one HRQOL domain provided prognostic information for each 
cancer site, alongside clinical and socio-demographic variables 
(Table  1), although which domain provided the greatest prog-
nostic power differed by cancer type.
A universal HRQOL domain with valid prognostic impact 
across cancer sites could not be identified. Physical functioning 
and nausea/vomiting were found to provide unique prognostic 
information in several but not all cancer sites.
By using longitudinal HRQOL data from a single advanced 
non–small cell lung cancer trial (n = 391), we investigated whether 
changes in HRQOL scores over time during chemotherapy treat-
ment can be prognostic of survival in addition to clinical charac-
teristics. It was found that a 10-point improvement in pain (from 
baseline to end of cycle 1) or social function (from baseline to end 
of cycle 2) was associated with a lower risk of death (12). Meanwhile 
pain, physical function, and dysphagia (single item of lung can-
cer–specific module QLQ-LC13 assessing treatment-related side 
effects [18]) were important baseline prognostic factors.
These studies provided further evidence that HRQOL can 
provide prognostic information beyond clinical measures, 
improve prognostic accuracy in cancer clinical trials, and yield 
informative factors to stratify and monitor patients for support-
ive interventions but that the actual prognostic HRQOL domains 
may vary across disease sites (9–12).
Table 1. Multivariable Cox regression analyses of survival (HRs of survival [95% CIs for socio-demographic, clinical, and HRQOL scales across 
the 11 cancer sites])*
HR (95%CI)
P
Cancer site Socio-demographic/clinical scales HRQOL scales
Colorectal Age
(≤60 vs >60 y)
1.27 (1.07 to 1.51)
.0011
Sex
(male vs female)
0.81 (0.68 to 0.98)
.0094
Nausea and  
vomiting
1.07 (1.04 to 1.11)
<.0001
Physical functioning
0.93 (0.90 to 0.99)
<.0001
Appetite loss
1.07 (1.04 to 1.11)
<.0001
Lung WHO PS
(good vs poor)
1.64 (1.18 to 2.82)
.0005
Sex
(male vs female)
0.76 (0.62 to 0.91)
.0008
Pain
1.08 (1.05 to 1.11)
<.0001
Physical functioning
0.94 (0.90 to 0.98)
.0006
Prostate WHO PS
(good vs poor)  
1.37 (1.15 to 1.63)
<.0001
- Role functioning
0.96 (0.94 to 0.98)
.006
Appetite loss
1.07 (1.03 to 110)
<.0001
Brain WHO PS
(good vs poor)
1.68 (1.36 to 2.10)
<.0001
Age
(≤60 vs >60 y)
1.55 (1.28 to 1.88)
<.0001
- Cognitive functioning
0.95 (0.90 to 0.97)
<.0001
Breast WHO PS
(good vs poor)
4.12 (1.78 to 9.52)
<.0001
Distant metastasis
(no vs yes)
21.45 (1.78 to 258.43)
<.0001
- Nausea and vomiting
1.17 (1.05 to 1.29)
.0011
Melanoma WHO PS
(good vs poor)
1.71 (1.08 to 2.70)
.0064
Sex
(male vs female)
0.61 (0.50 to 072)
<.0001
- Dyspnea
1.06 (1.03 to 1.10)
<.0001
Head & neck - Sex
(male vs female)
0.38 (0.21 to 0.71)
.0003
- Nausea and vomiting
1.14 (1.01 to 1.27)
.0097
Esophageal - - - Physical functioning
0.88 (0.80 to 0.96)
.0072
Ovarian - - - Nausea and vomiting
1.2 (1.10 to 1.30)
<.0001
Testicular - - - Role functioning
0.81 (0.67 to 0.95)
.0144
Pancreas - -  - Global health status/quality of life scale
 0.83 (0.71 to 0.95)
 .0073
* CI = confidence interval; HR = hazard ratio; HRQOL = health-related quality of life; WHO PS = World Health Organization performance status.
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Patients’ Self-Reports Along With Clinicians’ Scores 
Improve Survival Prediction
Typically, to estimate overall survival, clinician evaluation of 
symptoms is incorporated into a model of prognosis. When 
considering treatment options, a reliable survival prognosis 
is a valuable tool to make an informed decision. The clinician 
scoring of symptoms has conventionally been used. However, 
the weak agreement between clinician and patient reporting 
of symptoms is notable (19). In this PROBE analysis, the rela-
tive information gained in estimating survival when including 
baseline information of patient-reported symptoms was com-
pared with that reported by clinicians (assessed using Common 
Terminology Criteria for Adverse Events) across various disease 
sites, stages, and treatments. We found that for the six symp-
toms assessed at baseline—pain, fatigue, vomiting, nausea, 
diarrhea, and constipation—the models that considered both 
patient and clinician scores gained statistically significantly 
more prognostic OS accuracy, namely fatigue (P < .001), vomit-
ing (P = .01), nausea (P < .001), and constipation (P = .01), than 
models that considered clinician scores alone (13). The results 
of this retrospective PROBE analysis were acknowledged by 
the American Society of Clinical Oncology’s (ASCO) Annual 
Report on Progress Against Cancer as one among those with 
the greatest potential impact on patients’ lives (20), suggesting 
that adding patient-reported symptom scores to the traditional 
physician-based scoring system may result in a more accurate 
prognosis of survival.
Examining HRQOL Domain Clusters
Understanding the grouping between symptom and/or func-
tioning domains may aid clinicians in managing the symptom 
burden experienced by patients and may help policy makers 
develop psychosocial support plans. We attempted to identify 
how HRQOL domains cluster and which HRQOL indicators are 
linked to patients’ perception of overall quality of life (14). 
The results revealed physical (physical and role functioning, 
fatigue, pain), psychological (emotional and cognitive func-
tioning, insomnia), and gastrointestinal clusters (nausea/vom-
iting, appetite loss) emerging from the overall dataset. Each 
cluster had high to moderate internal consistency (α  =  .84, 
.64, and .67, respectively), indicating that the included scales 
are associated. The same clusters were found in subgroups 
defined according to socio-demographic and clinical charac-
teristics while some differences emerged among cancer sites. 
The global health status/quality of life scale was found to be 
part of the physical cluster in the overall dataset. This result 
was consistent across different levels of disease severity, but 
divergent results were seen across some cancer sites. These 
findings suggest that HRQOL domains are interrelated and 
form clusters; however, clusters vary by disease. Identifying 
the mechanisms that define the relationships between HRQOL 
domains is important for appropriate problem management 
and the identification of populations that could benefit from 
receiving tailored psychosocial support and/or improved sup-
portive care interventions.
Providing More Evidence-Based Data on Minimally 
Important Differences
MID refers to the smallest change or difference between 
HRQOL scores that is considered to be clinically relevant. This 
is an important notion with many implications, as it informs 
clinicians, patients, regulators, and clinical trialists as to which 
changes in HRQOL scores are important. For example, MIDs may 
be used to assess the value of a health care intervention or to 
compare treatments, to make adjustments in health care poli-
cies, or to inform a clinician’s decision to apply an intervention 
in a given situation (21). MIDs may also be useful in determining 
sample sizes in designing future RCTs. The methods commonly 
used to calculate MID are anchor-based or distribution-based 
(22–25). An example of the most widely used anchor-based 
approach was provided in the first estimation of MIDs for the 
QLQ-C30, which used the subjective significance questionnaire 
(21) to link changes in QLQ-C30 scores to patients’ ratings of sub-
jectively meaningful changes.
A PROBE analysis of two closed non–small cell lung can-
cer (NSCLC) RCTs (26–27) demonstrated that MID estimates 
for improvement appeared larger than those for deteriora-
tion in QLQ-C30 (15). The WHO performance status and weight 
change were used as clinical anchors. When anchoring with 
WHO performance status, the MID estimates for improvement 
or deterioration respectively were: physical functioning: (9, 4), 
role functioning: (14, 5), social functioning: (5, 7), global health 
status/quality of life scale: (9, 4), fatigue: (14, 6), and pain: (16, 
3). Statistically significant differences (P < .05) in HRQOL across 
groups defined by these anchors were noted for all scales except 
for social functioning. The results suggest that in patients with 
advanced NSCLC undergoing treatment MID may depend upon 
whether the patients’ WHO performance statuses are improv-
ing or worsening, but the results are not definitive. Additional 
MID analysis was carried out using HRQOL data from two EORTC 
high-grade glioma brain cancer RCTs (28–29). The WHO perfor-
mance status and the mini-mental state examination were 
used as clinical anchors to determine the MID in HRQOL change 
scores in the QLQ-C30 and the brain module, the QLQ-BN20. 
Based on WHO performance status, our findings provided the 
following estimates of the MID for improvement and deterio-
ration respectively: physical: (6, 9), role: (14, 12), and cognitive 
functioning: (8, 8), and global health status/quality of life scale: 
(7, 4), fatigue: (12, 9), and motor dysfunction: (4, 5). The results 
suggested that MID estimates for improvement and for dete-
rioration vary across the selected HRQOL scales; in these brain 
cancer studies, there was no clear indication that the MID for 
improvement was systematically larger or smaller than the MID 
for deterioration (16).
The above findings suggest that although current guidelines 
are helpful for general interpretation more research is needed to 
estimate and compare MIDs on the QLQ-C30 across various patient 
populations, eg, across different cancer sites (melanoma, ovarian, 
etc.) as well as across stages of disease. This is consistent with 
the recommendations of Revicki et al. (30) that the MID is not an 
immutable characteristic but may vary by population and context.
HRQOL Completion Time Windows: Do They 
Matter?
A key aspect in the design and analysis of HRQOL data is the 
timing of the assessments. In an appropriately designed clini-
cal trial, the protocol will state exactly when the HRQOL 
assessments are scheduled, eg, one to three days prior to each 
treatment cycle. However, deviations from these schedules are 
often encountered during the course of the trial as patients may 
not be able to complete the questionnaire at the scheduled time. 
Consequently, analyses of HRQOL data frequently use ‘comple-
tion time windows’ around the expected completion time (31). 
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A certain number of days before and after the scheduled treat-
ment cycle date may be allowed, so that all questionnaires 
completed within that period are assumed to belong to that 
particular cycle.
Such time intervals, rather than a single fixed visit, allow 
more flexibility in data collection, thereby minimizing miss-
ing data. The impact of these completion time windows was 
explored, involving RCTs of different cancer treatments, eg, 
radiotherapy and chemotherapy.
We examined whether the QLQ-C30 scores of cancer patients 
undergoing chemotherapy are affected by the specific time point 
before, during, or after treatment, at which the questionnaire is 
completed, and whether this could bias the overall treatment 
comparison analyses. Using linear mixed models for the analy-
ses of longitudinal data (31), we found statistically significant 
differences (P < .05) for during and after treatment comparisons 
in these trials (17). For all three closed RCTs, the longitudinal 
mixed models resulted in a better fit when the ‘completion 
time window’ variable was included. However, differences were 
not sufficient to change treatment effects. While in this case 
accounting for time of completion did not alter the interpre-
tation of treatment comparisons, findings might vary in other 
situations. Additional analyses are ongoing to replicate these 
results in radiotherapy clinical trials.
Discussion
The PROBE initiative used archived cancer clinical trials as the 
basis for pooled HRQOL data. Our exploratory work shows it is 
possible to pool trials from across the world in order to address 
key HRQOL issues. It demonstrated the statistically significant 
advantages that can be made when international and mul-
tidisciplinary scientists (clinicians, methodologists, and psy-
chologists of multinational background and diverse scientific 
experience), such as those who comprised the PROBE Advisory 
Board, are brought together and join forces under a common 
scope. The PROBE members’ specific mandate was to focus on 
the practical application of HRQOL in RCT research to critically 
explore important aspects of implementing HRQOL in cancer 
clinical trials. PROBE’s contribution to clinical research was rec-
ognized when one PROBE publication was featured as a “nota-
ble advance” that successfully informed and changed clinical 
practice according to ASCO’s annual report on progress against 
cancer, “Clinical Cancer Advances 2012” (20). We continue to 
encourage collaboration at every level and have raised these 
issues at the European Parliament, which has been very sup-
portive of our initiative (32).
PROBE investigated critical topics with a major impact on 
future psychosocial care. Key outcomes were identified for 
improving the survival prognostication using HRQOL data, col-
lected through the QLQ-C30. By exploring and identifying clus-
ters of HRQOL problems, evidence of symptom interrelation 
was found that can benefit patients and lead to improvement 
of symptom management. The MID varied across brain and 
lung cancer patients, indicating there is need for additional 
empirical investigation of MIDs. Last, it provided valuable evi-
dence on the importance of using completion time windows 
in the design of clinical trials and in the analysis of HRQOL 
outcomes. Yet, the variability of results and diversity of symp-
toms across cancer sites make the application and generaliza-
tion of the findings challenging. PROBE will undertake research 
to estimate and compare MIDs on the QLQ-C30 across various 
patient populations that will provide guidelines for general 
interpretation.
However, we must not gloss over several methodological and 
statistical challenges and problems that had to be overcome 
during the course of pooling HRQOL and clinical data to conduct 
these retrospective analyses. The lack of availability of common 
indicators important for a full investigation of the research 
question was a major challenge (eg, disease stage, medical his-
tory). Variability across clinical trials on many important com-
ponents, like the timing of assessments, made merging data 
a complex task. To address these challenges, we were forced 
to use complex methodological designs and techniques to 
account for heterogeneity (33). Dropout and nonadherence with 
HRQOL assessments at follow-up limited the available HRQOL 
data and presented considerable missing data challenges. The 
various data management systems used by different clinical 
trials organizations made pooling time consuming. Data pri-
vacy and ownership issues also made pooling difficult and, in 
some cases, precluded participation of interested researchers 
or groups. Equally challenging was the task of funding research 
dissemination via the most appropriate channels and media 
(ie, conference organization, press releases, etc.) to provide a 
greater understanding of HRQOL and anticancer treatment 
and boost public and clinical awareness. Infrastructure barri-
ers and the lack of specialized staff in cancer-related HRQOL 
were other issues we had to overcome to ensure project sus-
tainability. A  limitation of our research relates to the dispro-
portional representation of the study population because of the 
availability of large-scale studies within certain cancer types 
(eg, 3125 melanoma patients vs 78 esophageal cancer patients) 
(Figure 2). Another limitation is poor HRQOL compliance in can-
cer clinical trials and the lack of good longitudinal HRQOL data, 
which restricted our research mainly to baseline data. Going 
forward, one way to overcome the challenges that the pooled 
datasets present would be the use of standardized core clini-
cal trial datasets for outcome measures, standardized collec-
tion and coding, and more clinical trial data sharing. Uniform 
publication guidelines (34–35) will allow HRQOL data to be more 
consistently presented.
Likewise, constraints caused by study population and HRQOL 
compliance difficulties are expected to be overcome in the 
future with the inclusion of more recent academic and indus-
try RCTs with good compliance and longitudinal HRQOL data 
across various cancer sites.
In terms of future research, numerous analyses are being 
planned to make better use of the PROBE data and to help gain 
a better understanding of clinical trial data. Research topics 
under investigation include missing data, prognostic value of 
cancer-specific modules, MID in all cancer types, and joint mod-
eling of longitudinal HRQOL (36) with clinical outcomes (such as 
overall survival, progression-free survival, and other biomark-
ers). Further research correlating HRQOL with survivorship and 
biomarkers (which have now become a standard component of 
EORTC clinical trials) will also be investigated when the neces-
sary funds are secured. Long-term evaluations linking HRQOL to 
survivorship data are another goal.
The use of closed international clinical trials holds great 
promise for understanding patients’ unmet psychosocial and 
HRQOL needs. This research program has shown that expen-
sive prospective and lengthy studies are not always needed to 
answer specific research questions. Development of large-scale 
global collaborations such as the PROBE initiative has proven 
to be a valuable way of using existing data and benefits both 
patients and society by improving clinical care and understand-
ing cancer. Such a repository of data will prove useful for many 
years to come. An automated way of adding new trial data to 
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enrich the HRQOL dataset will be developed by the EORTC with 
the support of our international collaborators. The growth of 
PROBE with 10 newly closed and fully published EORTC RCTs 
and the inclusion of pharmaceutical clinical trial data will pro-
vide an even larger and ever-growing database. This will allow 
us to answer more complex and overarching questions on key 
topics in oncology, such as institutional compliance. However, 
access to datasets and the merging of data are complex, with 
difficult processes; we need to be realistic about the challenges 
and expenditure. We invite other clinical trial researchers who 
have an interest in HRQOL research to work with us, join us, 
share data, and increase the pool of data, so many more impor-
tant questions can be addressed and new questions can be 
developed.
In summary, we hope the PROBE initiative has shown that 
closed RCTs with HRQOL data can play an important role in the 
planning of future research, promote a better understanding 
of cancer care and the role of patient-reported HRQOL assess-
ments (37), and extend our knowledge of methodological issues 
in HRQOL assessment. This initiative has demonstrated the 
benefits of international collaboration in the field of HRQOL. 
Cooperation contributes considerably to improving the effi-
ciency and impact of research efforts, and only with increased 
collaboration across research groups can we address many of 
the outstanding HRQOL questions.
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